Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

JAMA

Volumn 292, Issue 21, 2004, Pages 2585-2590

  Graham, David J ^a   Staffa, Judy A ^a   Shatin, Deborah ^b   Andrade, Susan E ^c   Schech, Stephanie D ^b   La Grenade, Lois ^a   Gurwitz, Jerry H ^c   Chan, K Arnold ^d,e   Goodman, Michael J ^f   Platt, Richard ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Ctr for Hlth Care Plcy and Eval   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; AMBULATORY CARE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; UNITED STATES;

EID: 9644252909     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.21.2585     Document Type: Article

References (31)

1. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22: 441-457.
2. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
3. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
4. Ballantyne CM, Corsini A, Davidson MH, et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
5. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408-416.
6. Clouâtre Y, Leblanc M, Ouimet D, Pichette V. Fenofibrate-induced rhabdomyolysisin two dialysis patients with hypothyroidism [letter]. Nephrol Dial Transplant. 1999;14:1047-1048.
7. Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis [letter]. Diabetes Care. 2003;26:2482-2483.
8. Gorriz JL, Sancho A, Lopez-Martin JM, et al. Rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy. Nephron. 1996;74:437-438.
9. Layne RD, Sehbai AS, Stark LJ. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother. 2003;38:232-234.
10. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-917.
11. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096-1107.
12. Zocor. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004: 2113-2118.
13. Lipitor. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004: 2543-2546.
14. Gaist D, Garcia-Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy. Epidemiology. 2001;12:565-569.
15. Black C, Jick H. Etiology and frequency of rhabdomyolysis. Pharmacotherapy. 2002;22:1524-1526.
16. Omar MA, Wilson IP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
17. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med. 2002;346:539-540.
18. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205-207.
19. Shatin D, Drinkard C, Stergachis A. United Health Group. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York, NY: John Wiley & Sons; 2000:295-306.
20. Chan KA, Platt R. Harvard Pilgrim Health Care/Harvard Vanguard Medical Associates. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York, NY: John Wiley & Sons; 2000:285-294.
21. McAlister FA, Straus SE, Guyatt CH, Haynes RB; Evidence-Based Medicine Working Group. Users' guides to the medical literature, XX: integrating research evidence with the care of the individual patient. JAMA. 2000;283:2829-2836.
22. Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemiain diabetes mellitus and metabolic syndrome. Curr Opin Cardiol. 2003;18:301-308.
23. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiological and clinical perspectives. Clin Invest Med. 2001;24:258-272.
24. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002;25:649-663.
25. Backman JT, Kyrklund C, Kivistō KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122-129.
26. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Latila J, Neuvonen PJ. Plasma concentrations of active lovastatin are markedly increased by gemfibrozil but not by bezafirate. Clin Pharmacol Ther. 2001;69:340-345.
27. Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002;72:685-691.
28. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans. Drug Metab Dispos. 2002;30:505-512.
29. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042-1051.
30. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280-1287.
31. Kolata G. Health officials urge sharply lower cholesterol levels. New York Times. July 13, 2004:A1.